Balyasny Asset Management
SPRB

Balyasny Asset Management’s Spruce Biosciences SPRB Stock Holding History

Balyasny Asset Management’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.61M Hold
40,000
– – ﹤0.01% 1670
2025
Q4 		$3.48M Buy
+40,000
New +$4.29M ﹤0.01% 1583
2024
Q2 		– Sell
-300
Closed -$17.7K – 3219
2024
Q1 		$17.7K Buy
+300
New +$76.3K ﹤0.01% 2541

Other funds holding SPRB

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $1.92B AUM 31.26% 1-Year Est. Return
ECM
ExodusPoint Capital Management New York $12.6B AUM 30.13% 1-Year Est. Return

Balyasny Asset Management's SPRB Position: Q1 2026 in Review

Balyasny Asset Management held its Spruce Biosciences (SPRB) position steady in Q1 2026 at 40,000 shares worth $2.61M. The position accounts for ﹤0.01% of the portfolio, ranked #1670.

Balyasny Asset Management first reported a position in SPRB in Q1 2024 and has held it in 3 quarters since. The position peaked at $3.48M in Q4 2025. 32 funds tracked by Wall St. Rank hold SPRB as of Q1 2026.

  • Balyasny Asset Management held 40,000 shares of Spruce Biosciences worth $2.61M as of Q1 2026.
  • Balyasny Asset Management left its Spruce Biosciences share count unchanged in Q1 2026.
  • Spruce Biosciences made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #1670 holding.
  • Balyasny Asset Management first reported a position in Spruce Biosciences in Q1 2024 and has held it in 3 quarters since.
  • Balyasny Asset Management's Spruce Biosciences position peaked at $3.48M in Q4 2025.
  • 32 funds tracked by Wall St. Rank held Spruce Biosciences as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.